||This article includes a list of references, related reading or external links, but its sources remain unclear because it lacks inline citations. (June 2013)|
|Jmol-3D images||Image 1
|Molar mass||240.26 g mol−1|
|Melting point||206 to 207 °C (403 to 405 °F; 479 to 480 K) (hydrochloride)
231-232 °C ((R)-isomer)
|Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)|
|(what is: / ?)|
DON is in a class of compounds commonly known as alpha-methyl phenethylamines, or amphetamines and the full chemical name is 1-(2,5-dimethoxy-4-nitrophenyl)propan-2-amine. It has an active stereocenter and (R)-DON is the more active isomer. Concentrated solution is dark brown but transparent viscous liquid.
DON produces psychedelic and entheogenic effects that last up to 8–30 hours. In his book PiHKAL (Phenethylamines I Have Known And Loved), Alexander Shulgin lists a dosage of DON as being 3-4.5 mg orally. When dropped into nose, the dose is the same but onset is shorter. Dosages up to 7.5 mg reportedly produce high-intensity psychedelic effects with colorful visuals. There was a report of long-lasting psychosis in a young man living in Petrozavodsk, after taking 12.5 mg DON hydrochloride. The man accidentally used approximately 20 - 30 mg. There were no long-lasting physical complications. Unlike DOB, DON shows a visible stimulation effect, including muscular activity slightly similar to amphetamine. It also has been known to be more visual than most of its psychedelic amphetamine counterparts.
The mechanism that produces the hallucinogenic and entheogenic effects of DON is similar to that of DOB and other analogs, this being agonist activity at a number of serotonin receptors, primarily 5-HT2A, 5-HT2C and 5-HT1A.
The toxicity of DON is not known.
DON is unscheduled and unregulated in the United States, however because of its close similarity in structure and effects to DOM and DOB, possession and sale of DON may be subject to prosecution under the Federal Analog Act. DON is listed as a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act after the table of contents of Pihkal and Tihkal were added to the schedules.